The San Diego Kaiser Permanente Community Clinical oncology Program (SDKP CCOP) provides access to high quality clinical trials for its 400,000 members in San Diego. This application is designed to both maintain a successful program in clinical trials and expand involvement into cancer control programs. This is especially important as Kaiser Permanente is a non profit health maintenance organization whose patients only access to clinical trials is through the currently funded CCOP. The San Diego Kaiser Permanente Community Clinical oncology Program has remained active in both the CALGB and NSABP organizations. A highly centralized CCOP administrative structure has been instrumental in accessing the patient population eligible for cancer treatment and cancer control trials. Continuation of this CCOP will insure that accession to national clinical trials continues from this organization. In addition, a well organized core of physicians including medical oncologists, radiation therapists, surgeons and pathologists is already in place and functioning as an enthusiastic group with involvement in clinical trials. Quality has been and will continue to be an overriding concern of this CCOP and is evident from our research base audits and ability to follow a large number of patients enrolled on clinical trials. However resources are stressed to the limit with over 360 patients on active follow up with only 2 funded positions. The addition of another position as outlined in this application will enhance the ability of this CCOP to accrue in both cancer treatment and cancer control trials. Cancer Control accrual has been poor due in part to a paucity of such trials from the CALGB and the NSABP in the past. With the recent award of the NSABP Breast Cancer Prevention Trial to the SDKP CCOP, cancer control participation will increase significantly in the near future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045374-05
Application #
2091841
Study Section
Special Emphasis Panel (SRC (70))
Project Start
1989-06-12
Project End
1998-05-31
Budget Start
1994-06-01
Budget End
1995-05-31
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Kaiser Foundation Research Institute
Department
Type
DUNS #
City
Oakland
State
CA
Country
United States
Zip Code
94612
Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8
Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
Muss, Hyman B; Woolf, Susan; Berry, Donald et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-81
Dressler, Lynn G; Berry, Donald A; Broadwater, Gloria et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-97
Ahles, Tim A; Herndon 2nd, James E; Small, Eric J et al. (2004) Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer 101:2202-8
Graziano, S L; Tatum, A; Herndon 2nd, J E et al. (2001) Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:115-23
Stone, R M; Berg, D T; George, S L et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-53
Hayes, D F; Yamauchi, H; Broadwater, G et al. (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-11